NEWSROOM
Sono-Tek Reports Fiscal Second Quarter and First Half 2025 Financial Results, Record Backlog and Provides Revenue Guidance
Q2 Sequential Revenue Growth Meets Quarterly Guidance of 2%-5% Record Equipment and Service Backlog of $11.7 Million First Half Revenue Growth of 10% YOY, First Half Net Income Growth of 13% YOY Expects Continued Revenue Growth for Full Fiscal Year 2025 Conference Call Today at 10:00 am ET MILTON, N.Y., October 15, 2024 – PRISM MediaWire - Sono-Tek Corporation (Nasdaq: SOTK), the leading developer and manufacturer of ultrasonic coating systems, today reported financial results for the second...
Co-Founder of Shire Pharmaceuticals Appointed as Chief Operating Officer of Klotho Neurosciences
KLTO strengthens team with industry veteran and is poised to accelerate the development of its therapeutic candidates New York, NY, October 15, 2024 - PRISM MediaWire - Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biotechnology company pioneering cell and gene therapies for aging and age-related diseases, today announced the appointment of Peter Moriarty, Co-Founder of Shire Pharmaceuticals, as its Chief Operating Officer (COO). “We are thrilled to have Peter join Klotho...
Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform
Patent application covers key technology innovations for delivering therapeutic agents Proprietary technology enables precise delivery to improve safety and efficacy in oncology, cancer survivorship and immunotherapy Allowance provides broad IP protection for drug-delivery platform and extends market exclusivity for two lead clinical assets currently in Phase 2 trials PITTSBURGH, PA, October 15, 2024 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage...
SPZI: JP 3E Holdings, Inc. Accelerates Growth with Major Corporate Milestones Toward Uplisting
NEW YORK, October 14, 2024 – PRISM MediaWire - JP 3E Holdings, Inc. (OTC: SPZI), formerly Spooz, Inc., is excited to announce a series of significant corporate developments that mark a new era of growth and expansion for the company. These strategic initiatives include steps to uplist to the OTCQB market, filing a Form 10, following which, it will initiate 15c2-11 filing, become a fully reporting company under SEC guidelines, remove the "shell risk" designation, and implement a comprehensive...
In Light of World Mental Health Day, PRISM Highlights Mental Health Index Companies Making a Difference
New York, New York, October 10, 2024 - PRISM MediaWire - PRISM MediaWire - Mental health has not always been a topic to discuss as easily as other health related topics due to the stigma surrounding it. Those who have identified having a mental health condition typically do not seek the proper help or treatment for fear of judgement or admission to being unstable. The reality of it is that whether or not you have a condition, we all need to do things to ensure we have good mental health in the...
Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit
PITTSBURGH, Oct. 09, 2024 - PRISM MediaWire - Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced that CEO Jonathan Kaufman, PhD will be presenting at the 2024 Maxim Healthcare Virtual Summit that is being held on October 15 -17, 2024. Event: Lipella Presentation - 2024 Maxim Healthcare Virtual Summit Date: Thursday, October 17th, 2024...
SKYX Provides Corporate Update, including Significant Insider Buying
MIAMI, Oct. 09, 2024 - PRISM MediaWire - SKYX (NASDAQ: SKYX) (d/b/a "SKYX Technologies"), a highly disruptive smart platform technology company with over 97 issued and pending patents in the U.S. and globally, and which owns over 60 lighting and home décor websites with a mission to make homes and buildings become smart, safe, and advanced as the new standard, provides today a corporate update including significant insider buying. SKYX Secures $11 million equity preferred stock investment...
Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial
Results published in peer-reviewed journal, Clinical Cancer Research Study validates DetermaIO’s utility in identifying breast cancer patients most likely to benefit from atezolizumab DetermaIO targets a multi-billion-dollar addressable market in oncology diagnostics IRVINE, Calif., October 8, 2024 - PRISM MediaWire - Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced the peer-reviewed publication of positive data related to its proprietary gene expression test,...
Sono-Tek Announces Fiscal Second Quarter and First Half 2025 Earnings Conference Call
Conference Call on Tuesday, October 15, 2024 at 10:00 am ET MILTON, NY, October 8, 2024 – PRISM MediaWire - Sono-Tek Corporation (NASDAQ: SOTK), the leading developer and manufacturer of ultrasonic coating systems, today announced that the Company will hold a conference call to discuss its fiscal second quarter and first half 2025 financial results, ended August 31, 2024, on Tuesday, October 15, 2024 at 10:00 am ET. The second quarter and first half FY 2025 financial results press release will...
SKYX Secures $11 Million Strategic Investment at $2.00 Per Share, Preferred Stock Convertible, Led by Global Marriott Hotel-Chain Developer, Lance Shaner, Owner of over 60 Hotels, Primarily Marriotts
Management Emphasizes That It Has Sufficient Cash to Achieve Its Goals Including Recently Announced Collaborations and Being Cash Flow Positive During 2025 The $11 Million Investment includes Leading Builders and Hotel Developers MIAMI, October 07, 2024 - PRISM MediaWire - SKYX Platforms Corp. (NASDAQ: SKYX) (d/b/a SKYX Technologies) (the "Company" or "SKYX"), a highly disruptive smart platform technology company with more than 97 issued and pending patents globally and over 60 lighting and...